part1 NEW YORK, NY--(Marketwire -10/05/11)- In recent years the FDA has been heavily scrutinized for making the approval process more difficult for drug developers. A groundbreaking study released this year by the BIO and BioMedTracker finds that the overall success rate for drugs moving through clinical trials to FDA approval from late 2003 to the end of 2010 is a mere 10 percent. The Bedford Report examines the outlook for companies in the Biotechnology Industry and provides equity research on Geron Corporation (NASDAQ: GERN - News) and Nektar Therapeutics (NASDAQ: NKTR - News). Access to the full company reports can be found at:
News 
Market Data 
Discover 
